Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models

BACKGROUND: Anti-PD-1 immune checkpoint blockade is approved for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but few patients respond. Statin drugs (HMG-CoA reductase inhibitors) are associated with superior survival in several cancer types, including...

Descripción completa

Detalles Bibliográficos
Autores principales: Kansal, Vikash, Burnham, Andre J, Kinney, Brendan L C, Saba, Nabil F, Paulos, Chrystal, Lesinski, Gregory B, Buchwald, Zachary S, Schmitt, Nicole C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853267/
https://www.ncbi.nlm.nih.gov/pubmed/36650022
http://dx.doi.org/10.1136/jitc-2022-005940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853267/
https://www.ncbi.nlm.nih.gov/pubmed/36650022
http://dx.doi.org/10.1136/jitc-2022-005940

Ejemplares similares